Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

被引:20
作者
Varga, Gergely [1 ]
Nagy, Zsolt [2 ]
Demeter, Judit [2 ]
Kosztolanyi, Szabolcs [3 ]
Szomor, Arpad [3 ]
Alizadeh, Hussain [3 ]
Deak, Beata [4 ]
Schneider, Tamas [4 ]
Plander, Mark [5 ]
Szendrei, Tamas [5 ]
Varoczy, Laszlo [6 ]
Illes, Arpad [6 ]
Batai, Arpad [7 ]
Peto, Monika [7 ]
Mikala, Gabor [7 ]
机构
[1] Semmelweis Univ, Dept Internal Med 3, Kutvolgyi Ut 4, H-1125 Budapest, Hungary
[2] Semmelweis Univ, Dept Internal Med 1, Budapest, Hungary
[3] Univ Pecs, Dept Internal Med 1, Pecs, Hungary
[4] Natl Inst Oncol, Budapest, Hungary
[5] Markusovszky Univ, Teaching Hosp, Szombathely, Hungary
[6] Univ Debrecen, Inst Med, Clin Ctr, Dept Hematol, Debrecen, Hungary
[7] Natl Inst Hematol & Infect Dis, Dept Hematol & Stem Cell Transplantat, South Pest Cent Hosp, Budapest, Hungary
关键词
Multiple myeloma; Relapsed; Ixazomib; Named patient program; ORAL IXAZOMIB;
D O I
10.1007/s12253-019-00607-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ixazomib-Revlimid-Dexamethasone is an all-oral treatment protocol for multiple myeloma with a manageable tolerability profile which was available through a named patient program for Hungarian patients from December 2015 to April 2017. We analyzed the clinical characteristics and survival of 77 patients treated at 7 centers within this program. The majority of patients responded, we found complete response in 9, very good partial response in 8, partial response in 32, minor response or stable disease in 13 and progressive disease in 11 patients. Progression free survival was 11.4 months. There was a trend of longer progression free survival in those with 1 vs. >1 prior treatment, with equally good effectivity in standard risk and high risk cytogenetic groups. The adverse events were usually mild, none leading to permanent drug interruptions. There were 5 fatalities: 3 infections and 2 pulmonary embolisms. Our real word data support the use of Ixazomib-Revlimid-Dexamethasone as a highly effective and well tolerated oral treatment protocol for relapsed myeloma.
引用
收藏
页码:1615 / 1620
页数:6
相关论文
共 12 条
  • [1] Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma
    Al-Salama, Zaina T.
    Garnock-Jones, Karly P.
    Scott, Lesley J.
    [J]. TARGETED ONCOLOGY, 2017, 12 (04) : 535 - 542
  • [2] [Anonymous], 2017, BLOOD S1
  • [3] Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal
    Armoiry, Xavier
    Connock, Martin
    Tsertsvadze, Alexander
    Cummins, Ewen
    Melendez-Torres, G. J.
    Royle, Pam
    Clarke, Aileen
    [J]. PHARMACOECONOMICS, 2018, 36 (09) : 1073 - 1081
  • [4] Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
    Avet-Loiseau, Herve
    Bahlis, Nizar J.
    Chng, Wee-Joo
    Masszi, Tamas
    Viterbo, Luisa
    Pour, Ludek
    Ganly, Peter
    Palumbo, Antonio
    Cavo, Michele
    Langer, Christian
    Pluta, Andrzej
    Nagler, Arnon
    Kumar, Shaji
    Ben-Yehuda, Dina
    Rajkumar, S. Vincent
    San-Miguel, Jesus
    Berg, Deborah
    Lin, Jianchang
    van de Velde, Helgi
    Esseltine, Dixie-Lee
    di Bacco, Alessandra
    Moreau, Philippe
    Richardson, Paul G.
    [J]. BLOOD, 2017, 130 (24) : 2610 - 2618
  • [5] A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis
    Dimopoulos, Meletios Athanasios
    Kaufman, Jonathan L.
    White, Darrell
    Cook, Gordon
    Rizzo, Maria
    Xu, Yingxin
    Fahrbach, Kyle
    Gaudig, Maren
    Slavcev, Mary
    Dearden, Lindsay
    Lam, Annette
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (03) : 163 - +
  • [6] International uniform response criteria for multiple myeloma
    Durie, B. G. M.
    Harousseau, J-L
    Miguel, J. S.
    Blade, J.
    Barlogie, B.
    Anderson, K.
    Gertz, M.
    Dimopoulos, M.
    Westin, J.
    Sonneveld, P.
    Ludwig, H.
    Gahrton, G.
    Beksac, M.
    Crowley, J.
    Belch, A.
    Boccadaro, M.
    Turesson, I.
    Joshua, D.
    Vesole, D.
    Kyle, R.
    Alexanian, R.
    Tricot, G.
    Attal, M.
    Merlini, G.
    Powles, R.
    Richardson, P.
    Shimizu, K.
    Tosi, P.
    Morgan, G.
    Rajkumar, S. V.
    [J]. LEUKEMIA, 2006, 20 (09) : 1467 - 1473
  • [7] Hari P, 2018, J MED ECON, V29, P1
  • [8] Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
    Leleu, Xavier
    Masszi, Tamas
    Bahlis, Nizar J.
    Viterbo, Luisa
    Baker, Bartrum
    Gimsing, Peter
    Maisnar, Vladimir
    Samoilova, Olga
    Rosinol, Laura
    Langer, Christian
    Song, Kevin
    Izumi, Tohru
    Cleeland, Charles
    Berg, Deborah
    Lin, Huamao Mark
    Zhu, Yanyan
    Skacel, Tomas
    Moreau, Philippe
    Richardson, Paul G.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (08) : 985 - 993
  • [9] Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
    Mateos, Maria-Victoria
    Masszi, Tamas
    Grzasko, Norbert
    Hansson, Markus
    Sandhu, Irwindeep
    Pour, Ludek
    Viterbo, Luisa
    Jackson, Sharon R.
    Stoppa, Anne-Marie
    Gimsing, Peter
    Hamadani, Mehdi
    Borsaru, Gabriela
    Berg, Deborah
    Lin, Jianchang
    Di Bacco, Alessandra
    van de Velde, Helgi
    Richardson, Paul G.
    Moreau, Philippe
    [J]. HAEMATOLOGICA, 2017, 102 (10) : 1767 - 1775
  • [10] Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
    Moreau, P.
    Masszi, T.
    Grzasko, N.
    Bahlis, N. J.
    Hansson, M.
    Pour, L.
    Sandhu, I.
    Ganly, P.
    Baker, B. W.
    Jackson, S. R.
    Stoppa, A. -M.
    Simpson, D. R.
    Gimsing, P.
    Palumbo, A.
    Garderet, L.
    Cavo, M.
    Kumar, S.
    Touzeau, C.
    Buadi, F. K.
    Laubach, J. P.
    Berg, D. T.
    Lin, J.
    Di Bacco, A.
    Hui, A. -M.
    van de Velde, H.
    Richardson, P. G.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (17) : 1621 - 1634